Remove Antibody Remove Business Development Remove Contract Manufacturing Remove Licensing
article thumbnail

Regeneron Reports Third Quarter 2020 Financial and Operating Results

The Pharma Data

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. Evinacumab , an antibody to ANGPTL3.

Sales 52
article thumbnail

The challenges and trends of cell & gene therapies 

Drug Discovery World

Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. Víctor Cervera-Carrascón, Tilt Bio. . Another area that can be tough to manoeuvre is IP, as we saw recently over the disputes surrounding CRISPR.

article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business (4) in the first three quarters of 2020 , is now included within the Hospital therapeutic area for all periods presented. Hospital products, which grew 10% operationally to $2.3